Compare XAIR & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | EOCN |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.9M |
| IPO Year | 2015 | 2013 |
| Metric | XAIR | EOCN |
|---|---|---|
| Price | $2.07 | $2.25 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 50.6K | 6.7K |
| Earning Date | 11-11-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | N/A |
| Revenue This Year | $6.52 | N/A |
| Revenue Next Year | $104.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $2.05 |
| 52 Week High | $8.19 | $3.80 |
| Indicator | XAIR | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 34.58 |
| Support Level | $2.05 | $2.32 |
| Resistance Level | $2.49 | $2.98 |
| Average True Range (ATR) | 0.29 | 0.29 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 13.74 | 30.08 |
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.